Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 65 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR Amivantamab Plus Lazertinib Shows Superior Efficacy to Osimertinib in First-Line Treatment... July 5, 2024 Sister Is There To Comfort Her Little Brother As He Battles... September 10, 2019 New Year’s Wishes 2016 December 29, 2022 Can a Biopsy Make My Cancer Spread? March 18, 2021 Load more HOT NEWS Reflections from our chief clinician: The essential role of our research... Get the Most out of Seasonal Fruits! Students Invent Disposable Core Biopsy Needle to Make the Procedure Cheaper BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing...
